Patient and Tumor Characteristics
| DOSI study | DOSI + PET study | |||||
| Characteristic | Parameter | No. of patients | % | Parameter | No. of patients | % |
| Total number | 84 | 64 | ||||
| Age (y) | ||||||
| Mean | 56 | 55.9 | ||||
| SD | 10.4 | 11.4 | ||||
| Range | 35–77 | 35–77 | ||||
| Tumor size (mm) | ||||||
| Mean | 37.5 | 39.3 | ||||
| SD | 16.8 | 17.1 | ||||
| Range | 7–97 | 7–97 | ||||
| Histology | ||||||
| IDC | 76 | 90.5 | 56 | 87.5 | ||
| ILC | 2 | 2.4 | 2 | 3.1 | ||
| Other | 6 | 7.1 | 6 | 9.4 | ||
| Estrogen receptor status | ||||||
| Positive | 47 | 55.9 | 37 | 57.8 | ||
| Negative | 37 | 44.1 | 27 | 42.2 | ||
| Progesterone receptor status | ||||||
| Positive | 37 | 44.1 | 32 | 50 | ||
| Negative | 47 | 55.9 | 32 | 50 | ||
| HER2 status | ||||||
| Positive | 18 | 21.4 | 14 | 21.9 | ||
| Negative | 66 | 78.6 | 50 | 78.1 | ||
| Nodal status | ||||||
| Positive | 58 | 69 | 43 | 67.2 | ||
| Negative | 26 | 31 | 21 | 32.8 | ||
| Histologic assessment after NAC | ||||||
| pCR (ypT0/is, ypN0) | 13 | 15.5 | 11 | 17.2 | ||
| pCR (ypT0/is, ypN1) | 3 | 3.5 | 3 | 4.7 | ||
| Non-pCR | 68 | 81 | 50 | 78.1 | ||
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; HER2= human epidermal growth factor receptor 2.